Krishanu Saha

The paper uses CRISPR screening to identify genes that enhance nonviral genome editing efficiency in human cells, finding six genes that increase editing efficiency by up to five-fold.

This paper introduces a method to enhance T cell therapy by using a CAR targeting uPAR to eliminate dysfunctional T cells through directed fratricide.

Autofluorescence imaging informs manufacturing conditions that enhance yield and metabolic fitness of CAR T cells for neuroblastoma.

This study evaluates subretinal delivery of Cas9 ribonucleoproteins in mice and pigs, showing variable editing efficiency and highlighting species-specific challenges for therapeutic translation.

This paper shows that low-dose radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in neuroblastoma by improving tumor regression and immune response.

This study uses CRISPR to disrupt an inhibitory receptor in NK cells and insert a GD2-targeting CAR, creating potent NK cells against GD2+ melanoma.

The paper uses CRISPR-Cas9 to edit the App gene in mice, reducing Alzheimer's disease symptoms and showing long-term benefits.

This study shows that metabolic priming during CAR T cell manufacturing reduces glycolysis and enhances memory phenotypes, improving in vivo persistence against GD2+ tumors.

This study develops non-viral nanocapsules for in vivo CRISPR-Cas9 delivery to edit neuronal DNA in mice, achieving efficient and safe genome editing in specific neuron types.

This paper demonstrates nonviral base editing of a KCNJ13 mutation in a mouse model of retinal degeneration, preserving vision through functional rescue of Kir7.1 channels.

The paper evaluates CRISPR base editors for correcting a KCNJ13 mutation causing LCA16, finding high on-target efficiency but negligible channel function due to bystander edits and mRNA structural issues.

This study uses iPSC-RPE models to evaluate gene augmentation and editing for Best disease, finding that some mutations respond to gene therapy while others require genome editing.

This paper introduces a CRISPR/Cas9 strategy to edit APP and manipulate the amyloid pathway in Alzheimer's disease by reducing β-cleavage and Aβ while increasing α-cleavage.

This study develops micropatterned substrates to monitor reprogramming of human somatic cells, identifying nuclear features that distinguish fully from partially reprogrammed cells.